Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022

リキッドバイオプシーの世界市場予測(~2022年)

◆タイトル:Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022
◆商品コード:MAM-MD4456
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年9月25日
◆ページ数:206
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、リキッドバイオプシーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、癌種類別分析、バイオマーカー別分析、製品別分析、需要先別分析、リキッドバイオプシーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global liquid biopsy market is projected to reach USD 2,047.9 Million by 2022 from USD 715.7 Million in 2017, at a CAGR of 23.4%. Factors such as increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the market.
The number of companies offering liquid biopsy devices is increasing, globally. Major market players are focusing on strengthening their product offerings, mergers and acquisitions, and geographic presence by entering into contracts and agreements with other established players in the market. For instance, in January 2017, Bio-Rad Laboratories, Inc. (US) entered into a definitive agreement with RainDance Technologies, Inc. (US) to acquire the latter. The acquisition will result in Bio-Rad’s expansion into next-generation sequencing applications.

The report analyzes the liquid biopsy market by product, circulating biomarker, clinical application, application, end user, and region. On the basis of product and service, the market is segmented into assay kits, instruments, and services. The assay kits segment is expected to account for the largest share of the global market in 2017. Factors such as the increasing demand for liquid biopsy tests, increasing applications of liquid biopsies, and the need for reliable and specific assays are expected to drive the market in the coming years.

On the basis of clinical application, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The therapy selection segment is expected to account for the largest share of the global market in 2017. This is due to the potential benefits of liquid biopsy in therapy selection.

On the basis of application, the liquid biopsy market is segmented into cancer and non-cancer applications. The cancer application segment is expected to account for the largest share of the global market in 2017. Based on end user, the market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories). In 2017, the reference laboratories segment is expected to account for the largest share of the liquid biopsy market. The large share of this segment is attributed to the increased volume of liquid biopsy test samples outsourced to reference laboratories.

Geographically, the global liquid biopsy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America is expected to dominate the market which can be attributed to the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals. The APAC region is expected to register the highest CAGR during the forecast period. Growth in this market can be attributed to a number of factors such as rising disposable incomes in the middle-class populations infrastructural developments, rising penetration of cutting-edge diagnostic technologies, the growing focus of global life science companies in this region, government initiatives to increase awareness about genome-based diagnostic procedures, and the increasing incidence rate of cancer.

In 2016, QIAGEN N.V. (Netherlands), Roche Diagnostics (US), and Illumina, Inc. (US) dominated the global liquid biopsy market. Some of the other players competing in this market are Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDxHealth SA (US).

【レポートの目次】

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 19)
2.1 Research Approach
2.1.1 Secondary Data
2.1.1.1 Secondary Sources
2.1.2 Primary Data
2.1.2.1 Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study

3 Executive Summary (Page No. – 27)

4 Premium Insights (Page No. – 31)
4.1 Liquid Biopsy Market: Overview
4.2 Global Market, By Clinical Application (2017)
4.3 Global Market: Geographic Growth Opportunities
4.4 Global Market: Geographic Mix
4.5 Global Market: Established vs Emerging Markets

5 Market Overview (Page No. – 35)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Prevalence of Cancer
5.2.1.2 Increasing Preference for Noninvasive Procedures
5.2.1.3 Initiatives Undertaken By Government and Global Health Organizations
5.2.1.4 Technological Advancement to Augment Market Revenues
5.2.1.5 Rising Emphasis on Personalized Medicine
5.2.1.6 Availability of Funding for Liquid Biopsy R&D
5.2.2 Restraints
5.2.2.1 Low Sensitivity and Specificity
5.2.3 Opportunities
5.2.3.1 Growing Interest in Liquid Biopsy
5.2.4 Challenges
5.2.4.1 Unclear Regulatory and Reimbursement Scenario

6 Liquid Biopsy Market, By Product and Service (Page No. – 46)
6.1 Introduction
6.2 Assay Kits
6.3 Instruments
6.4 Services

7 Liquid Biopsy Market, By Circulating Biomarker (Page No. – 52)
7.1 Introduction
7.2 Circulating Tumor Cells
7.3 Circulating Tumor DNA (CTDNA)
7.4 Cell-Free DNA
7.5 Extracellular Vesicles (Evs)
7.6 Other Circulating Biomarkers

8 Liquid Biopsy Market, By Clinical Application (Page No. – 61)
8.1 Introduction
8.2 Early Cancer Screening
8.3 Therapy Selection
8.4 Treatment Monitoring
8.5 Recurrence Monitoring

9 Liquid Biopsy Market, By Application (Page No. – 67)
9.1 Introduction
9.2 Cancer Applications
9.2.1 Lung Cancer
9.2.2 Breast Cancer
9.2.3 Colorectal Cancer
9.2.4 Prostate Cancer
9.2.5 Liver Cancer
9.2.6 Other Cancers
9.3 Non-Cancer Applications

10 Liquid Biopsy Market, By End User (Page No. – 80)
10.1 Introduction
10.2 Reference Laboratories
10.3 Hospitals and Physician Laboratories
10.4 Academic and Research Centers
10.5 Other End Users

11 Liquid Biopsy Market, By Region (Page No. – 86)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 UK
11.3.4 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Rest of Asia Pacific
11.5 Rest of the World (RoW)

12 Competitive Landscape (Page No. – 146)
12.1 Market Ranking Analysis

13 Company Profiles (Page No. – 147)
(Overview, Products Offered, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments.)*
13.1 Biocept, Inc.
13.2 Qiagen N.V.
13.3 Roche Diagnostics
13.4 Bio-Rad Laboratories, Inc.
13.5 Myriad Genetics, Inc
13.6 Menarini-Silicon Biosystems
13.7 Trovagene, Inc.
13.8 Guardant Health, Inc.
13.9 Mdxhealth SA
13.10 Genomic Health, Inc.
13.11 Raindance Technologies, Inc
13.12 Thermo Fisher Scientific Inc.
13.13 Illumina, Inc.

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key Relationships Might Not Be Captured in Case of Unlisted Companies.

14 Appendix (Page No. – 195)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.4 Introducing RT: Real-Time Market Intelligence
14.5 Available Customizations
14.6 Related Reports
14.7 Author Details

List of Tables (133 Tables)

Table 1 Conferences and Awareness Programs on Liquid Biopsy
Table 2 Liquid Biopsy Products Launched in Recent Years
Table 3 Liquid Biopsy Market: Funding (2014 – 2017)
Table 4 Companies Selling/Developing Liquid Biopsy Tests for Oncology, in the US
Table 5 Global Market, By Product and Service, 2015–2022 (USD Million)
Table 6 Global Market for Assay Kits, By Country, 2015–2022 (USD Million)
Table 7 Specifications: Ngs and Ddpcr for Cancer Liquid Biopsies
Table 8 Global Market for Instruments, By Country, 2015–2022 (USD Million)
Table 9 Liquid Biopsy Market for Services, By Country, 2015–2022 (USD Million)
Table 10 Advantages and Limitations of CTCS, CTDNA, and Exosomes
Table 11 Global Market, By Circulating Biomarker, 2015–2022 (USD Million)
Table 12 Companies Active in the CTCS Segment
Table 13 Global Market for Circulating Tumor Cells, By Country, 2015–2022 (USD Million)
Table 14 Global Market for Circulating Tumor DNA, By Country, 2015–2022 (USD Million)
Table 15 Global Market for Cell-Free DNA, By Country, 2015–2022 (USD Million)
Table 16 Global Market for Extracellular Vesicles, By Country, 2015–2022 (USD Million)
Table 17 Liquid Biopsy Market for Other Circulating Biomarkers, By Country, 2015–2022 (USD Million)
Table 18 Global Market, By Clinical Application, 2015–2022 (USD Million)
Table 19 Global Market for Early Cancer Screening, By Country/Region, 2015–2022 (USD Thousands)
Table 20 Global Market for Therapy Selection, By Country/Region, 2015–2022 (USD Million)
Table 21 Global Market for Treatment Monitoring, By Country/Region, 2015–2022 (USD Million)
Table 22 Global Market for Recurrence Monitoring, By Country/Region, 2015–2022 (USD Million)
Table 23 Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 24 Global Market for Cancer Applications, By Country/Region, 2015–2022 (USD Million)
Table 25 Global Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 26 Global Market for Lung Cancer, By Country/Region, 2015–2022 (USD Million)
Table 27 Global Market for Breast Cancer, By Country/Region, 2015–2022 (USD Million)
Table 28 Global Market for Colorectal Cancer, By Country/Region, 2015–2022 (USD Million)
Table 29 Liquid Biopsy Market for Prostate Cancer, By Country/Region, 2015–2022 (USD Million)
Table 30 Global Market for Liver Cancer, By Country/Region, 2015–2022 (USD Million)
Table 31 Global Market for Other Cancers, By Country/Region, 2015–2022 (USD Million)
Table 32 Global Market for Non-Cancer Applications, By Country/Region, 2015–2022 (USD Million)
Table 33 Global Market, By End User, 2015–2022 (USD Million)
Table 34 Global Market for Reference Laboratories, By Country/Region, 2015–2022 (USD Million)
Table 35 Liquid Biopsy Market for Hospitals and Physician Laboratories, By Country/ Region, 2015–2022 (USD Million)
Table 36 Global Market for Academic and Research Centers, By Country/ Region, 2015–2022 (USD Million)
Table 37 Global Market for Other End Users, By Country/Region, 2015–2022 (USD Million)
Table 38 Global Market, By Region, 2015–2022 (USD Million)
Table 39 Estimated New Cases of Cancer in 2017, US
Table 40 North America: Liquid Biopsy Market, By Country, 2015–2022 (USD Million)
Table 41 North America: Market, By Product & Service, 2015–2022 (USD Million)
Table 42 North America: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 43 North America: Market, By Clinical Application, 2015–2022 (USD Million)
Table 44 North America: Market, By Application, 2015–2022 (USD Million)
Table 45 North America: Liquid Biopsy Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 46 North America: Market, By End User, 2015–2022 (USD Million)
Table 47 US: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 48 US: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 49 US: Market, By Application, 2015–2022 (USD Million)
Table 50 US: Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 51 US: Market, By Clinical Application, 2015–2022 (USD Million)
Table 52 US: Market, By End User, 2015–2022 (USD Million)
Table 53 Overview of the Breast, Cervical, and Colorectal Cancer Screening Programs Across Canada
Table 54 Canada: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 55 Canada: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 56 Canada: Market, By Application, 2015–2022 (USD Million)
Table 57 Canada: Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 58 Canada: Market, By Clinical Application, 2015–2022 (USD Million)
Table 59 Canada: Market, By End User, 2015–2022 (USD Million)
Table 60 Europe: Liquid Biopsy Market, By Country, 2015–2022 (USD Million)
Table 61 Europe: Market, By Product & Service, 2015–2022 (USD Million)
Table 62 Europe: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 63 Europe: Market, By Application, 2015–2022 (USD Million)
Table 64 Europe: Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 65 Europe: Market, By Clinical Application, 2015–2022 (USD Million)
Table 66 Europe: Market, By End User, 2015–2022 (USD Million)
Table 67 Germany: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 68 Germany: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 69 Germany: Market, By Application, 2015–2022 (USD Million)
Table 70 Germany: Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 71 Germany: Market, By Clinical Application, 2015–2022 (USD Million)
Table 72 Germany: Market, By End User, 2015–2022 (USD Million)
Table 73 France: Key Market Indicators
Table 74 France: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 75 France: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 76 France: Market, By Application, 2015–2022 (USD Million)
Table 77 France: Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 78 France: Market, By Clinical Application, 2015–2022 (USD Million)
Table 79 France: Market, By End User, 2015–2022 (USD Million)
Table 80 UK: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 81 UK: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 82 UK: Market, By Application, 2015–2022 (USD Million)
Table 83 UK: Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 84 UK: Market, By Clinical Application, 2015–2022 (USD Million)
Table 85 UK: Market, By End User, 2015–2022 (USD Million)
Table 86 RoE: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 87 RoE: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 88 RoE: Market, By Application, 2015–2022 (USD Million)
Table 89 RoE: Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 90 RoE: Market, By Clinical Application, 2015–2022 (USD Million)
Table 91 RoE: Market, By End User, 2015–2022 (USD Million)
Table 92 Asia Pacific: Liquid Biopsy Market, By Country, 2015–2022 (USD Million)
Table 93 Asia Pacific: Market, By Product & Service, 2015–2022 (USD Million)
Table 94 Asia Pacific: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 95 Asia Pacific: Market, By Application, 2015–2022 (USD Million)
Table 96 Asia Pacific: Market, By Type of Cancer, 2015–2022 (USD Million)
Table 97 Asia Pacific: Market, By Clinical Application, 2015–2022 (USD Million)
Table 98 Asia Pacific: Market, By End User, 2015–2022 (USD Million)
Table 99 Japan: Key Market Indicators
Table 100 Japan: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 101 Japan: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 102 Japan: Market, By Application, 2015–2022 (USD Million)
Table 103 Japan: Market, By Type of Cancer, 2015–2022 (USD Million)
Table 104 Japan: Market, By Clinical Application, 2015–2022 (USD Million)
Table 105 Japan: Market, By End User, 2015–2022 (USD Million)
Table 106 China: Key Market Indicators
Table 107 China: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 108 China: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 109 China: Market, By Application, 2015–2022 (USD Million)
Table 110 China: Market, By Type of Cancer, 2015–2022 (USD Million)
Table 111 China: Market, By Clinical Application, 2015–2022 (USD Million)
Table 112 China: Market, By End User, 2015–2022 (USD Million)
Table 113 India: Key Market Indicators:
Table 114 India: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 115 India: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 116 India: Market, By Application, 2015–2022 (USD Million)
Table 117 India: Market, By Type of Cancer, 2015–2022 (USD Million)
Table 118 India: Market, By Clinical Application, 2015–2022 (USD Million)
Table 119 India: Market, By End User, 2015–2022 (USD Million)
Table 120 RoAPAC: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 121 RoAPAC: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 122 RoAPAC: Market, By Application, 2015–2022 (USD Million)
Table 123 RoAPAC: Market, By Type of Cancer, 2015–2022 (USD Million)
Table 124 RoAPAC: Market, By Clinical Application, 2015–2022 (USD Million)
Table 125 RoAPAC: Market, By End User, 2015–2022 (USD Million)
Table 126 RoW: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 127 RoW: Liquid Biopsy Circulating Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 128 RoW: Market, By Application, 2015–2022 (USD Million)
Table 129 RoW: Market, By Type of Cancer, 2015–2022 (USD Million)
Table 130 RoW: Market, By Clinical Application, 2015–2022 (USD Million)
Table 131 RoW: Market, By End User, 2015–2022 (USD Million)
Table 132 Liquid Biopsy Market, By Key Player, 2016
Table 133 Chf to USD Conversion Rates (2014-2016)

List of Figures (44 Figures)

Figure 1 Liquid Biopsy: Market Segmentation
Figure 2 Research Design
Figure 3 Market Size Estimation: Bottom-Up Approach
Figure 4 Market Size Estimation: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Liquid Biopsy Market, By Product and Service, 2017 vs 2022
Figure 7 Market, By Clinical Application, 2017 vs 2022
Figure 8 Liquid Biopsy Market, By Application, 2017 vs 2022
Figure 9 Market, By End User, 2017 vs 2022
Figure 10 Geographical Snapshot of the Global Liquid Biopsy Market
Figure 11 Increasing Cancer Prevalence—Major Growth Driver for the Global Market
Figure 12 Therapy Selection Segment to Dominate the Market in 2017
Figure 13 North America to Account for the Largest Share of the Liquid Biopsy Market in 2017
Figure 14 Asia Pacific to Grow at the Highest CAGR During the Forecast Period
Figure 15 Emerging Markets to Grow at Higher CAGRs From 2017 to 2022
Figure 16 Liquid Biopsy Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Estimated New Cancer Cases and Estimated Deaths in US (2017)
Figure 18 Cancer Prevalence and Mortality Rate, By Country (2012)
Figure 19 Pubmed Publications—Liquid Biopsy
Figure 20 Estimated New Cancer Cases and Deaths (2016)
Figure 21 North America: Liquid Biopsy Market Snapshot
Figure 22 US: Cancer Statistics
Figure 23 Canada: Cancer Statistics
Figure 24 Europe: Proportion of Deaths Due to Cancer in the Eu (2013)
Figure 25 Europe: Deaths Due to Cancer in the Population Aged 65 and Over (2013)
Figure 26 Germany: Cancer Incidence and Prevalence, 2010 vs 2015
Figure 27 UK: Estimated Number of People Living With Cancer
Figure 28 RoE: Incidence and Prevalence of Cancer, 2015
Figure 29 Asia Pacific: Liquid Biopsy Market Snapshot
Figure 30 Japan: Cancer Incidence and Prevalence Number, 2010 vs 2015
Figure 31 China: Cancer Incidence and Prevalence Number, 2010 vs 2015
Figure 32 India: Cancer Incidence and Prevalence Number, 2010 vs 2015
Figure 33 Rest of Asia Pacific: Number of Cancer Cases, 2015
Figure 34 Biocept, Inc.: Company Snapshot (2016)
Figure 35 Qiagen N.V.: Company Snapshot (2016)
Figure 36 Roche Diagnostics: Company Snapshot (2016)
Figure 37 Bio-Rad Laboratories, Inc.: Company Snapshot (2016)
Figure 38 Myriad Genetics, Inc: Company Snapshot (2016)
Figure 39 Menarini Group: Company Snapshot (2016)
Figure 40 Trovagene Inc.: Company Snapshot (2016)
Figure 41 Mdxhealth: Company Snapshot (2016)
Figure 42 Genomic Health, Inc.: Company Snapshot (2016)
Figure 43 Thermo Fisher Scientific: Company Snapshot (2016)
Figure 44 Illumina Inc.: Company Snapshot (2016)



【レポートのキーワード】

リキッドバイオプシー、生検、癌、バイオマーカー、肺癌、乳がん、結腸直腸がん、前立腺癌

★調査レポート[リキッドバイオプシーの世界市場予測(~2022年)] ( Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022 / MAM-MD4456) 販売に関する免責事項
[リキッドバイオプシーの世界市場予測(~2022年)] ( Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022 / MAM-MD4456) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆